TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31395124

Group type: EXPERIMENTAL
Intervention: Patients presenting with syncope to the ED
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Patients hospitalized (47% of total)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Long-term follow-up (2 years)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Long-term follow-up (2 years) in hospitalized patients
Number of subjects: 1397
Study: 31395436

Group type: EXPERIMENTAL
Intervention: Zilver PTX stents
Number of subjects: 13
Study: 31395600

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant (AlloSCT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (AuSCT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: AlloSCT
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: AuSCT
Number of subjects: 500
Study: 31395751

Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily) and Buparlisib (80 mg once daily)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination therapy (Binimetinib and Buparlisib)
Number of subjects: 89
Study: 31396142

Group type: EXPERIMENTAL
Intervention: Flavonoids- and Omega 3-Based Compound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31396983

Group type: EXPERIMENTAL
Intervention: PEX168 200 μg (single abdominal subcutaneous injection)
Number of subjects: 23
Study: 31397291

Group type: EXPERIMENTAL
Intervention: Mobile Directly Observed Therapy (Mobile DOT)
Number of subjects: 34
Study: 31397845

Group type: EXPERIMENTAL
Intervention: Insulin degludec (Tresiba)
Number of subjects: 1167
Study: 31398081

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV) and Brentuximab Vedotin (1.8 mg/kg IV) every 3 weeks
Number of subjects: 30
Study: 31398082

Group type: EXPERIMENTAL
Intervention: AZD1775 (150 mg/d) in combination with gemcitabine (1,000 mg/m²) and radiation
Number of subjects: 34
Study: 31398204

Group type: EXPERIMENTAL
Intervention: School-based deworming intervention, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no deworming intervention)
Number of subjects: 0
Study: 31398245

Group type: COMPARATOR
Intervention: Ovarian cortex tissue obtained from 10 TS patients after unilateral ovariectomy; analysis of X chromosomal content of oocytes and granulosa cells.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ovarian cortex stromal cells from TS patients; analysis of X chromosomal content.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Analysis of extra-ovarian cells (lymphocytes, buccal cells, urine cells) from the same patients.
Number of subjects: 10
Study: 31398307

Group type: EXPERIMENTAL
Intervention: Segesterone acetate/ethinyl estradiol contraceptive vaginal system (SA/EE CVS)
Number of subjects: 2070
Study: 31399043

Group type: EXPERIMENTAL
Intervention: HSV-1 based oncolytic immunotherapy with GALV-GP-R
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination with PD1/L1-targeted immune checkpoint blockade
Number of subjects: 29
Study: 31399109

Group type: EXPERIMENTAL
Intervention: Stimulated mesenchymal stem cells (S-MSCs) cultured in endothelial growth medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 31399255

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg daily)
Number of subjects: 48
Study: 31399439

Group type: EXPERIMENTAL
Intervention: Skills, Confidence, and Preparedness Index (SCPI) used in diabetes self-management education (DSME) program
Number of subjects: 405
Study: 31399936

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg QD for 8-21 days)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ribociclib (21-day-on, 7-day-off schedule after surgery)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ribociclib (monotherapy)
Number of subjects: 3
Study: 31400109

Group type: EXPERIMENTAL
Intervention: Enhanced standard of care of automated text-messaging and monitoring (AMM) and repeat HIV/STI testing assessment procedures (n=690)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Online group peer support via private social media plus AMM (n=270)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Coaching that is strengths-based, youth-centered, unscripted, based on common practice elements of EBI, available over 24 months, and delivered by near-peer paraprofessionals via text, phone, and in-person, plus AMM (n=270)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Online group peer support plus coaching and AMM (n=270)
Number of subjects: 1500
Study: 31400325

Group type: EXPERIMENTAL
Intervention: Preoperative systematic inflammation-immune score (SIS)
Number of subjects: 660
Study: 31400383

Group type: EXPERIMENTAL
Intervention: Ephrin A2-targeted liposomal prodrug at an equitoxic dose of 50 mg taxane/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel at a dose of 10 mg/kg
Number of subjects: 0
Study: 31400502

Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tyrosine Kinase Inhibitors
Number of subjects: 0
Study: 31400961

Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with idarubicin and cytarabine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 44
Study: 31401102

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Post-anthracycline N-terminal prohormone of brain natriuretic peptide
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Baseline LVEF and LVEF change post-anthracycline
Number of subjects: 222
Study: 31401588

Group type: EXPERIMENTAL
Intervention: Medicorp module (3-day pre-HO intervention)
Number of subjects: 208
Study: 31401607

Group type: COMPARATOR
Intervention: tDCS (sham, 0.5 mA, 1 mA, 1 mA, 2 mA) applied over the dorsolateral prefrontal cortex for up to three, 20 min sessions.
Number of subjects: 10
Study: 31401903

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31401975

Group type: EXPERIMENTAL
Intervention: Neural-network analysis using four CK metabolic parameters
Number of subjects: 178
Study: 31402238

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) - 3 doses
Number of subjects: 37
Study: 31402382

Group type: EXPERIMENTAL
Intervention: Sero-low group (10 volunteers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sero-high group (9 volunteers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sero-high group
Number of subjects: 19
Study: 31402867

Group type: EXPERIMENTAL
Intervention: Loxapine; dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study: 31403338

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31403585

Group type: EXPERIMENTAL
Intervention: The newly developed 50-point score for predicting cesarean delivery after labor induction.
Number of subjects: 1692

Group type: COMPARATOR
Intervention: Levine score (risk calculator for cesarean delivery).
Number of subjects: 1692

Group type: COMPARATOR
Intervention: Modified Bishop score.
Number of subjects: 1692

Group type: EXPERIMENTAL
Intervention: The newly developed score in the derivation set.
Number of subjects: 1692

Group type: EXPERIMENTAL
Intervention: The newly developed score in the internal validation set.
Number of subjects: 1692
Study: 31403970

Group type: EXPERIMENTAL
Intervention: Newly detected AF persistent >24 h
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Newly detected AF
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cortex-involved lesions
Number of subjects: 243
Study: 31404542

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg twice per day for 7 days)
Number of subjects: 68
Study: 31404569

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Any framing message
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: HCP recommendation
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Vaccine-offered condition
Number of subjects: 1747
Study: 31404802

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg open-label for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21
Study: 31404882

Group type: EXPERIMENTAL
Intervention: Executive Function (EF) training
Number of subjects: 709

Group type: COMPARATOR
Intervention: Poor Executive Function (EF)
Number of subjects: 709
Study: 31405666

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 18
Study: 31405822

Group type: EXPERIMENTAL
Intervention: Rogaratinib at 800 mg twice daily
Number of subjects: 126
Study: 31405950

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 13
Study: 31406470

Group type: EXPERIMENTAL
Intervention: Adherence to the MyPlate meal pattern
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Consumption of fizzy drinks and fast food ≥1 time/week
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Consumption of fresh fruit
Number of subjects: 843
Study: 31406564

Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccines with autologous tumor antigens
Number of subjects: 72
Study: 31406569

Group type: EXPERIMENTAL
Intervention: Fluid optimisation and blood pressure control using a non-invasive system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 31406690

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 128
Study: 31406985

Group type: EXPERIMENTAL
Intervention: Parechovirus A infections
Number of subjects: 158
Study: 31407002

Group type: EXPERIMENTAL
Intervention: Drug-drug combinations (specific combinations include amoxicillin/clavulanate and diclofenac with steroid hormones)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single drugs
Number of subjects: 48
Study: 31407130

Group type: EXPERIMENTAL
Intervention: Platelets and growth factors (GFs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Platelets
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: P-selectin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soluble VCAM-1 and ICAM-3
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Higher VCAM-1 and ICAM-3 and lower P-selectin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Circulating markers of vascular injury
Number of subjects: 26
Study: 31407236

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 38

Group type: COMPARATOR
Intervention: glimepiride
Number of subjects: 38
Study: 31407321

Group type: EXPERIMENTAL
Intervention: Episodic migraine
Number of subjects: 13064

Group type: EXPERIMENTAL
Intervention: Chronic migraine
Number of subjects: 13064

Group type: COMPARATOR
Intervention: Not in a romantic relationship
Number of subjects: 13064

Group type: COMPARATOR
Intervention: In a relationship but not living together
Number of subjects: 13064
Study: 31408415

Group type: EXPERIMENTAL
Intervention: 18 or more MET hours per week of physical activity
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Less than 3 MET hours per week of physical activity
Number of subjects: 1218
Study: 31408438

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 3

Group type: COMPARATOR
Intervention: mTOR signaling
Number of subjects: 3
Study: 31408668

Group type: EXPERIMENTAL
Intervention: Prophylactic Breast Irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31409287

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (prophylaxis) in the OTTILIA registry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified (control group in FIRST registry)
Number of subjects: 0
Study: 31409297

Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) as home-based support for PMTCT services
Number of subjects: 70
Study: 31409398

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E immunization
Number of subjects: 195
Study: 31409407

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) sessions: 60 sessions of 90 minutes at 100% oxygen at 2 ATA with 5 min air breaks every 20 min, 5 days per week.
Number of subjects: 88
Study: 31409544

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioural therapy (Tele-CBT)
Number of subjects: 43
Study: 31409575

Group type: EXPERIMENTAL
Intervention: T-VEC (talimogene laherparepvec)
Number of subjects: 60
Study: 31410175

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation ablation (IRE) therapy
Number of subjects: 3
Study: 31410294

Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes intervention (4-week health literacy training, disease knowledge education, 2 home visits, monthly phone counseling for 24 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes intervention
Number of subjects: 30
Study: 31410626

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) added to endoscopic ultrasound fine-needle aspiration (EUS-FNA)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 206
Study: 31410738

Group type: EXPERIMENTAL
Intervention: SBT success (n=61)
Number of subjects: 78

Group type: COMPARATOR
Intervention: SBT failure (n=17)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Extubation success (n=39)
Number of subjects: 78
Study: 31410779

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 455662
Study: 31410787

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg once daily
Number of subjects: 611
Study: 31410992

Group type: EXPERIMENTAL
Intervention: Broccoli soup (300 mL portions, three times a week for four weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no broccoli soup)
Number of subjects: 18
Study: 31411386

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (single intravenous dose ≤20 mg/kg or 2 consecutive doses of 10 mg/kg given 84 days apart)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (single 10 mg/kg dose)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (in phase 3 trials)
Number of subjects: 1607
Study: 31411949

Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent intravenous cisplatin 30 mg/m²
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy regimen
Number of subjects: 114
Study: 31412732

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 803
Study: 31412789

Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with near-complete removal of infused water (89%) during insertion
Number of subjects: 86

Group type: COMPARATOR
Intervention: Water exchange (WE)
Number of subjects: 86
Study: 31412834

Group type: EXPERIMENTAL
Intervention: Personalized Exercise Questionnaire (PEQ)
Number of subjects: 95
Study: 31412836

Group type: EXPERIMENTAL
Intervention: Dengue force-of-infection estimation
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Dengue infection rates
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Estimation of primary dengue infections
Number of subjects: 2556
Study: 31412874

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31412906

Group type: EXPERIMENTAL
Intervention: Monitoring regional cerebral oxygen saturation (rSO2)
Number of subjects: 0
Study: 31412935

Group type: EXPERIMENTAL
Intervention: DS-8895a (20 mg/kg) infused intravenously every 2 weeks
Number of subjects: 37
Study: 31413142

Group type: EXPERIMENTAL
Intervention: Veledimex (VDX) 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Corticosteroids (dexamethasone) >20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Corticosteroids (dexamethasone) ≤20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Veledimex (VDX) 20 mg cohort with corticosteroids >20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Veledimex (VDX) 20 mg cohort with corticosteroids ≤20 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Number of subjects: 31
Study: 31413177

Group type: EXPERIMENTAL
Intervention: PARP1 inhibition using AZD2281-olaparib and ABT-888-veliparib
Number of subjects: 0
Study: 31413844

Group type: EXPERIMENTAL
Intervention: Management of patients with AS in tertiary care settings
Number of subjects: 800

Group type: COMPARATOR
Intervention: Management of patients with AS in primary/secondary care settings
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Transition from asymptomatic to symptomatic status
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Diagnostic steps and treatment decisions
Number of subjects: 800
Study: 31413865

Group type: EXPERIMENTAL
Intervention: Second-line TNF inhibitors (TNFis)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Other biological agents (tocilizumab (TCZ), rituximab, or abatacept)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Tocilizumab (TCZ)
Number of subjects: 203
Study: 31413923

Group type: EXPERIMENTAL
Intervention: Pexa-Vec plus Best Supportive Care (BSC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pexa-Vec plus BSC
Number of subjects: 129
Study: 31413963

Group type: EXPERIMENTAL
Intervention: SAPP (Strength, Agility, Plyometric, and Secondary Prevention exercises)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SAPP + PERT (SAPP with Perturbation Training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Criterion-based postoperative rehabilitation (MOON)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Criterion-based postoperative rehabilitation with extended preoperative rehabilitation (Delaware-Oslo)
Number of subjects: 40
Study: 31414072

Group type: EXPERIMENTAL
Intervention: Expanded Vegetable Questionnaire
Number of subjects: 0
Study: 31414121

Group type: EXPERIMENTAL
Intervention: Risk-benefit analysis using rank-based method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-benefit analysis using partial-credit method
Number of subjects: 0
Study: 31414251

Group type: EXPERIMENTAL
Intervention: Unstressed spontaneous breathing (baseline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stressed spontaneous breathing (with resistance)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Assisted spontaneous breathing (pressure support at low and high assist levels)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Assisted spontaneous breathing (neurally adjusted ventilatory assist - NAVA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall analysis of Eadi, breathing pattern, esophageal pressure-time product (PTPeso), and work of breathing (WOB)
Number of subjects: 13
Study: 31414348

Group type: EXPERIMENTAL
Intervention: Educational palliative care intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study: 31414396

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) adherence strategies informed by shared decision-making (SDM)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) adherence strategies
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 46
Study: 31415245

Group type: EXPERIMENTAL
Intervention: Adoptive lymphocyte transfer from an elite controller (approximately 22 billion cells infused within 6 hours)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Adoptive lymphocyte transfer from an elite controller
Number of subjects: 1
Study: 31415351

Group type: EXPERIMENTAL
Intervention: Re-surgery (meshectomy/selective neurectomy)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 172
Study: 31415416

Group type: EXPERIMENTAL
Intervention: Shujinjianyao pill (SJJYP) for 4 weeks
Number of subjects: 0
Study: 31415566

Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment for Chagas disease, median dose 9.75 mg/kg/day three times a day (TID) for 1 month
Number of subjects: 10
Study: 31415936

Group type: EXPERIMENTAL
Intervention: FSH, DHEA, LH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 45

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study: 31416443

Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measures (PROMs) questionnaires administered before surgery, at 6 months, and at 12 months post-surgery
Number of subjects: 0
Study: 31416527

Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1 h algorithm
Number of subjects: 3123

Group type: COMPARATOR
Intervention: Extended algorithm
Number of subjects: 3123
Study: 31416921

Group type: EXPERIMENTAL
Intervention: Repeated training on joint assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single training on joint assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-performed assessments of joints and DAS28-CRP
Number of subjects: 0
Study: 31417440

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive-Behavioral Therapy
Number of subjects: 0
Study: 31417958

Group type: EXPERIMENTAL
Intervention: Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) combined with systemic chemotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 66
Study: 31418129

Group type: EXPERIMENTAL
Intervention: Adults with Autism Spectrum Disorder (ASD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typically developed adults (TD)
Number of subjects: 0
Study: 31419019

Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve replacement (TPVR)
Number of subjects: 409
Study: 31419065

Group type: EXPERIMENTAL
Intervention: AT1R-AA >40 U/mL
Number of subjects: 94

Group type: COMPARATOR
Intervention: AT1R-AA <40 U/mL
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Increased concentrations of AT1R-AA
Number of subjects: 94
Study: 31419329

Group type: EXPERIMENTAL
Intervention: THN102 100/1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: THN102 100/1, 100/3, 100/9
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: THN102 100/1 and 100/9
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: THN102
Number of subjects: 20

Group type: COMPARATOR
Intervention: MOD100
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 20
Study: 31420042

Group type: EXPERIMENTAL
Intervention: SM04690, a small-molecule inhibitor of the Wnt signaling pathway
Number of subjects: 0